PWPS
FDMT icon

Pinnacle Wealth Planning Services’s 4D Molecular Therapeutics FDMT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.33K Hold
100
– – ﹤0.01% 2545
2026
Q1 		$931 Hold
100
– – ﹤0.01% 2565
2025
Q4 		$750 Buy
+100
New +$1.01K ﹤0.01% 2614

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Pinnacle Wealth Planning Services's FDMT Position: Q2 2026 in Review

Pinnacle Wealth Planning Services held its 4D Molecular Therapeutics (FDMT) position steady in Q2 2026 at 100 shares worth $1.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2545.

Pinnacle Wealth Planning Services first reported a position in FDMT in Q4 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Pinnacle Wealth Planning Services held 100 shares of 4D Molecular Therapeutics worth $1.33K as of Q2 2026.
  • Pinnacle Wealth Planning Services left its 4D Molecular Therapeutics share count unchanged in Q2 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2545 holding.
  • Pinnacle Wealth Planning Services first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.